

Pub E25
Claim 18 (Amended). An isolated polypeptide having an amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81 or 83.

D6
Claim 19 (Amended). An isolated polypeptide according to claim 18, wherein the N-terminal methionine residue of the polypeptide is deleted.

Claim 20 (Amended). An isolated polypeptide according to claim 18, wherein the secretory amino acid sequence of the polypeptide is deleted.

Pub E23
D6
Claim 25 (Amended). A vaccine composition comprising a polypeptide having at least 95% identity with a second polypeptide having an amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 10, 14, 16, 55, 58, 60, 62 to 69, 71 to 75, 77 to 79, 81 or 83, or a combination thereof and a pharmaceutically acceptable carrier, diluent or adjuvant.

Please add the following claims:

Pub E24
✓ Claim 32. (New) An isolated polypeptide having an amino acid sequence of SEQ ID NOs: 2, 10, 55, 58, 64, 65 or 66.

D1
Claim 33. (New) A vaccine composition comprising a polypeptide having an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 55, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO:

/ 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO:65, SEQ ID NO: 66, SEQ ID NO: 67,
SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73,
SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO: 79 .

E4

Claim 34. (New) A vaccine composition according to claim 25 wherein the polypeptide lacks an N-terminal methionine residue.

Δ

Claim 35. (New) A vaccine composition according to claim 25 wherein the polypeptide lacks a secretory amino acid sequence.

Claim 36. (New) An isolated polypeptide having at least 95 % identity with a second polypeptide comprising an amino acid sequence of any one of SEQ ID NOs.10, 58, 64, 65 and 66.

Claim 37. (New) A vaccine composition comprising a having at least 95% identity with a second polypeptide having an amino acid sequence of any one of SEQ ID NOs, 10, 58, 64, 65 and 66 or a combination thereof_ and a pharmaceutically acceptable carrier, diluent or adjuvant.

REMARKS

Favorable reconsideration of the subject application, in view of the amendments above and comments below, is respectfully requested.